June 12, 2017 Market Strategies Newsletter Market Strategies Newsletter Sample Issue

MARKET STRATEGIES NEWSLETTER

Where To Invest Newsletter

Balanced Investing Strategies To Make Money In Up Or Down Markets

A Publication of Princeton Research, Inc. (<u>www.PrincetonResearch.com</u>)

Contributing Staff: Michael King, Charles Moskowitz



Proven Trading Success

Our Most Recent TRADE ALERTS

14% Loss on SPY Calls in 1 Day
177% Gains on SPY Calls in 1 Day
50% Loss on SPY Calls in 3 Days
55% Gains on SPY Calls in 2 Days
485% Gains on SIG Calls in 10 Days
134% Gains on SIG Calls in 7 Days
91% Gains on SPY Calls in 6 Days
50% Loss on SMG Calls in 7 Days
100% Gains on SPY Calls in 2 Days
112% Gains on SPY Calls in 2 Days
125% Gains on SPY Calls in 2 Days
125% Gains on SPY Calls in 2 Days
100% Gains on SPY Puts in 1 Day
57% Gains on JBLU Calls in 8 Days
66% Loss on SPY Puts in 2 Days

6% Loss on SPY Puts in 1 Day 21% Loss on SPY Puts in 1 Day 18% Gains on SPY Calls in 1 Day 91% Gains on SPY Calls in 1 Day 50% Loss on SPY Calls in 1 Day 63% Gains on SPY Calls in 2 Days 100% Gains on SPY Calls in 1 Day 175% Gains on SPY Puts in 3 Days 57% Gains on JBLU Calls in 8 Days

See all trades in past newsletter issues.

Remember, these trades are based on your participation in the Subscriber Members Only TEXTING SERVICE TO RECEIVE ALL UPDATES.

New Trades Will Be TEXTED To MEMBERS



For Free Where To Invest Your Money Now High Return Investments Trade Alerts Go To: PrincetonResearch.com/alerts.htm

SPECIAL RATES Available for VIP MEMBERSHIP

Get the <u>lowest full membership rates available</u>.

NOTE: This is a Sample Issue Only!

TO GET OUR TRADE ALERTS BY TEXT MESSAGE AND

THE COMPLETE VIP MEMBERS ONLY MARKET STRATEGIES NEWSLETTER ISSUES

Visit: PrincetonResearch.com/join.htm

Follow Our Marketed Weathered, Time Tested Trading Rules That PROTECT YOUR CAPITAL And SECURE PROFITS

Now you can profit from investing trade alerts from our traders with over 75 combined years of successful investing experience.

- Make Money In Up Or Down Markets -- Our trading alerts balanced investing strategies are designed and proven to make money in up or down markets.
- ➤ <u>Done For You</u> All the stock options picking, research and trading analysis is done for subscribers. This is not a 'class' or a 'training course'... this is us doing ALL the work... from research to sending you a text on what to trade, along with recommended amounts...
- SAFETY We strictly follow our Tested, Market Weathered Trading Rules that are proven time and time again to protect our (and now your) investment capital from losses while effectively allowing us to Keep The Profits We Make.

So even though we trade options to get the profits you see above -- We can do it with minimal risk and Maximum Profit Potential.

You Don't Need To Learn Any Trading Skills Or Do Any Time Consuming Analysis and Tracking

+++ We DO IT ALL FOR YOU! +++

We tell you where, when and how much to trade and you get to sit back and enjoy the rewards!

The specific buy and sell trading alerts are sent directly to you by e-mail and text message. So you can get in on and cash out on our winning trades fast and at the right time.

Get Started with Any Amount - Follow our recommended trading guidelines for a \$10,000 portfolio or invest more or invest less -- Whatever you are comfortable with. Your investment is protected because Time Tested Trading Rules PROTECT YOUR CAPITAL And KEEP YOUR PROFITS.

Join Us Today.
Lock in the <u>Lowest Membership Rates Available HERE</u>



2 FOR 1 BONUS:

Your Membership includes access to both:

Trade Alerts by Text Message and e-mail AND The Market Investing Strategies Newsletter Full Members Only Edition

Our Where To Invest Now For Profits In Up or Down Markets Newsletter is more compact, informative, effective and quicker to read then the major, big name publications. AND there are NO ADS to wade through.

The Members Edition Newsletter is sent to you by e-mail Monday Mornings and available in the Members Area along with our archive of past issues.

SPECIAL RATES Available for VIP MEMBERSHIP

Get the lowest full membership rates available.

A Sample of the Where To Invest Now Newsletter Information Our Members Get Follows

<u>Investing Trade Alerts</u> Charles Moskowitz Discussion

Open Positions:

Long 10 HL July 6 Calls Long 6 BBRY June 11.50 Calls

Funds in Use \$ 362

DID "FANG" FINALLY GET BITTEN ???

Week 23 was tremendous. We had another great trade in SIG calls, as well as a couple of SPY trades late in the week. The gain was \$1,682 (clearly biggest of the year) bringing YTD gains to \$8566. We have only 2 small open trades in BBRY and HL with only \$362 of funds in use.

The correction in "FANG" started on Friday with what might have been a Flash Crash in AMZN with a move from \$1012 to 927 before closing \$978-32. The others; FB \$155 to 146 to close \$149-5, GOOGL \$1005 to 953 to close 971-33, and NFLX \$166 to 154 to close \$158-7.85. This was not a big surprise since all these names had made parabolic moves to the upside. What was a surprise was the fact

that the DJIA was up 90, DJ Transports rallied off 9266 to close 9327 down only 4.26, S&P 500 - \$2.02, Russell +6 while the NASDAQ was down \$113 (or 1.8%). The internals for the NYSE were 2:1 *positive* and the NASDAQ A/D was 1:1 with only the volume showing any weakness. Unbelievably, the difference was primarily the 235 million in the above mentioned FANG group plus AAPL, TSLA, and NVDA. I was concerned with the break and sold the TBT position since there might be a flight to safety trade in Treasuries, but after seeing the comeback I'll probably take another look at that one again.

The A.A.I.I. Sentiment numbers showed a gain in bulls at the expense of the neutral numbers, while bearish was slightly lower. This wasn't anything major and the numbers are all around historical norms.

What is more important this week will be how the market reacts to the Fed's expected rate hike. It is clearly been discussed to death as an absolute, but we'll have to hear what their statement is regarding further action. The flattening of the yield curve is troublesome to me, since if things don't pick up, the Fed doesn't have the room to lower rates much to help.

Again, as mentioned for the last several weeks as long as the volatility remains low I will trade the SPY from either side as the opportunities present themselves. *CAM*

<u>Investing Trade Alerts Summary</u> \$10,000 Trading Account Trade Table

DATE	TRADES	PRICE	COST	PROCEEDS	RESULTS
06/09	Bought 10 SPY June9th 243.50 Calls and	0.07	70	60	10 Loss
	sold the same day @ 0.06 for small loss				
06/09	Bought 10 SPY June 9 th 243 Calls and	0.18	180	500	320 Gain
	sold them Same day @ 4 0.50				
06/09	Sold 10 SPY June9th 244 Calls @ \$ 0.30 (50% Loss Rule)	1.09		300	310 Loss
06/07	Bought 6 BBRY June 11.50 Calls	0.22	132		
06/07	Sold Short 10 SPY June 9 th 244.50 Calls expired worthless on June 9th	0.34		340	340 Gain
06/09	Sold 2 SIG June 55 Calls	3.75		750	622 Gain
06/07	Sold 2 SIG June 55 Calls	1.50		300	172 Gain
	(100% Profit Rule + Gap)				
06/06	Bought 6 TBT July 36Calls and Sold them on	0.84	504	654	150 Gain

	June 9 th @ \$ 1.09				
06/06	Bought 10 SPY June9th 244 Calls	0.61	610		
06/05	Bought 10 HL July 6 Calls	0.23	230		
06/05	Sold 2 SJM June 130 Calls	2.99		598	278 Gain
06/05	Sold 5 SPY June9th 243.50 Calls	1.19		595	285 Gain
06/05	Sold 6 SMG June 90 Calls	0.20		120	165 Loss
06/02	Sold 5 SPY June9th 243.50 Calls	1.24		620	310 Gain
06/02	Sold 2 SJM June \$130 Calls 100% Profit Rule	3.50		700	360 Gain
06/01	Bought 5 SPY June9th 243.50 Calls	0.62	310		
06/01	Bought 4 SIG June \$55 Calls	0.64	256		
06/01	Bought 10 SPY June 9 th 243.50 Calls	0.62	620		
05/30	Bought 1 SMG June9th 243.50 Calls	0.60	60		
05/30	Bought 5 SMG June 90 Calls	0.45	225		
05/01	Bought 2 SJM June \$ 130 Calls	1.60	320		

3rd Week expiration when the month is listed without a date

Previous closed out trades not listed here may be seen in previous market letters in the VIP Subscribers Members Area.

Remember, these trades are based on your participation in the Subscriber Members Only TEXTING SERVICE TO RECEIVE ALL UPDATES.

NOTE: In texting we have a limited amount of words. In the interest of brevity:

The Quantity and Strike Price for each trade is specific. 1=January, 2=February

Trading is hypothetical. We may trade weekly options and they are noted: SPY 1/25 147 for SPY Jan 25th 147 Calls or Puts.

New Trades Will Be TEXTED To MEMBERS

Fundamental Analysis Stocks To Buy with Stops

Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses. All indicated on the table below, balance is critical.

Alibaba has made a few points. We are raising the stop loss price.

Semiconductors are a leader on Nasdaq. We remain long SIMO.

We have no position in Alcoa AA. If long use the 50 day price m.a. as (\$32.80) a risk point.

Flushing Financial FFIC fell to and held the 50 day price moving average on March 3rd, which was a buying opportunity. We would buy the Flushing Financial.

Boeing is on its way to \$ 200.

We are not involved with Bristol Myers.

Hecla Mining is a buy as long as it is above the 13 day price moving average.

We took profits on ENZ and want to buy at lower prices.

The HDGE is not yet relevant at this time. It is a decent long as long as it can trade above its 13 day price moving average.

Symbol	Name	Business Description	PE	P/S	MV mln	Price	Buy or Sell Limit	Stop Loss Or offset
BABA	Alibaba	China; more of a retailer than Amazon	50.67	13.21	275.5B	139.80	Bought @ \$ 111 on 4/7/17 opening	Raising stop loss to \$129x
AMZN	Amazon	Catalog & Mail Order	189	2.90	394B	1006.73 Long	Stopped out \$ 976	\$ 976x
SIMO	Silicon Motion	Semiconductor solutions for mobile storage and communications	9.7	2.5	1.39B	53.77	Bought 39.10 01/28/17	49.40x
CIO	City Office REIT	Real Estate Investment Trust high quality Offices	292	5.8	396Mln	12.58	Re Bought at 12.12	11.50x
TPC	Tutor Perini	Construction	12	0.25	1.3B	27.10 Stopped out28.90 05/04	19.40 10/31/16	Looking for place to re-buy
SAVE	Spirit Airlines	Discount Airline	13	1.6	3.6B	54.70	48.10	Buy on a dip to \$ 52 or close above

								\$54.40
BMY	Bristol Myers	Biopharmaceutical Products	28	5.1	94.9B	53.75 No position	Sold at 52.80x	Has no direction
ВА	Boeing	Aerospace, commercial jetliners, military systems	14	0.85	81B	189.80	Long at 132 10/04/16	New stop loss at \$ 179
HL	Hecla Mining	Basic Materials	44	3.61	1.7B	5.83 Look for re-entry	Long at 5.30 5/5/17	A good long
FFIC	Flushing Financial	Bank Holding company Savings and loans	13	3,5	592Mln	29.45	19.10 06/27	50 day m.a. at 27.45
AA	Alcoa	Aluminum Processing and Technology	N/A	0.4	9.5B	32.95	21.15 originally bought 2/8/16	\$ 32.10 - 32.75 support
ENZ	Enzo Biochem	Life Sciences	NA	1.35	134M	10.35	Bought at 5.13 10/7/16 Looking to re-buy	Sold on Opening Monday 4/3/17 Sold 8.43
BAC	Bank of America	Commercial Bank	10	2.02	165.3B	23.51	Bought at 15.42 9/30/16	23.60x stopped out on 3/21/17
HDGE	Advisor Shares	Ranger Bear ETF				8.69	Stopped out on 5/24	Must close above 8.83 to be long

MARKET LABORATORY – WEEKLY CHANGES

Prices are copied from <u>Barron's Weekly</u> and <u>Yahoo Finance</u> and may be incorrect.

Dow	Nasdaq	S&P 500	Transportation	Russell 2000	Nasdaq100
21,271.97	6207.92	2431.77	9327.88	1421.71	5741.94
+65.68	-97.88	-7.30	-3.84	+16.32	-139.51
+0.31%	-1.55%	-0.30%	-0.04%	+1.16%	-2.37%
Gold (spot) 1268.50 -8.30 -0.65%	Silver July 17.223 -0.302 -1.7%	Crude June 45.83 -1.83 -3.8%	Heating Oil 143.12 -5.36 -3.6%	Unleaded Gas 1.5017 -7.54 -4.8%	Natural Gas 3.039 +0.04 +1.3%

VIX 10.70 +0.95 +9.7%	Put/Call Ratios S&P 100 132/100's +22/100's	Put/Call Ratios CBOE Equity 60/100's -4/100's	Bonds 154-07 -0-19 2.95% -0-06%	10 Yr. Note 126-135 -055 2.26%- 0+01%	Copper 257.45 +0.85 +0.3%
CRB Inflation Index 176.76. -1.20 -0.7%	Barron's* Confidence 75.6 -1.3	S&P100 1071.90 -2.46 -0.23%	5 Yr. Note 118-09 -0-06 1.79%-0.045%	Dollar 97.28 +0.61 +0.63%	DJ Utilities 724.85 -7.78 -1.06%
AAII Confidence Index Average	Bullish 35.4% +8.5% 38.4%	Bearish 29.5% -2.0% 30.30%	Neutral 35.1% -6.5% 30.96%	M1 Money Supply +9.40% May 29 th	M2 Money Supply +6.09% May 29 th

^{*} Component Change in the Confidence Index

M1...all money in hands of the public, Time Deposits Traveler's Checks, Demand Deposits

M2.. adds Savings and Money Market Accounts both compared with the previous year.

Market Strategies Technical Information

S	UPPORT	RESISTANCE
S&P 500	2403	2470
NASDAQ (QQQ)	138.40	143.90
Trans	9060	9450
DOW	21,050	21,440
TLT	122.60	126.20

Market Strategies \$100,000 Trading Account

There were ten closed out options positions last week covering the usual multitude of different industries. The net was another substantial weekly gain of \$ 3,364.

There were seven winners and three losing trades. Gains the previous week were \$ 2,249, which make the total gain for the last two weeks at \$ 5,613.

The options expire on the third Friday of each Month unless otherwise posted.

The Stock table has the following 20 positions:

AGQ, AMBA, BBRY, EYES (2), GLYC, GSAT, HL(2), MOS (2), OILU, NUGT, REPR, RWM, SAN, SLV, SPXU, TEXQY, TWTR

The options call for a \$ 2,500 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically.

Money management is based on a hypothetical \$ 100,000.

The 20 stock positions would cost \$82,064

The two long options positions; the 12 BBRY June 11.50 Calls, and the 20 HL July \$6 Calls would require \$724

when combined with the stock requirement of \$82,064 equals \$82,788.

which leaves excess cash of \$17,212

These figures are approximate and there might be errors.

The trading is hypothetical and we do not count commission costs.

Executions that have occurred at or near the open or close of trading sometimes vary from our actual numbers. For example, when something opens down and it is through our price, we take the next trade whether it is an uptick or continues lower. This sometimes results in a 50% trade that is slightly above or below the exact number.

Previous Week's Recommendations and Rules for the Market Strategies \$100,000 Portfolio Trading Account

- ➤ All options count for about \$ 2,500.00 for model portfolio calculations unless otherwise stated
 - When the option has doubled sell half the position
 - Stop Loss protection is either half or offered with each trade
- ➤ The cost of the option is the asking price (or the price between the bid and ask, whichever is more realistic)
 - > The options will be followed until closed out.
 - Option Symbols are stock symbol with expiration month and strike price

Option	Cost	Date	Sold	Date	Profit/ (Loss)
SPYJune9th 243.50 20 lots	Calls 0.07	06/09/17	0.06	06/09/2017	(\$20)
SPY June 9 th	Calls 0.18	06/09/17	0.50	06/09/2017	\$ 640

06/06/17	1.09	06/09/2017	\$ 300
06/09/17	0.34	06/07/2017	\$ 680
06/06/17	0.30	06/09/2017	(\$620)
06/01/17	1.50 (100% profit Rule + Gap)	06/07/2017	\$ 344
	3.75 Sold Balance	06/09/2017	\$ 1244
05/30/17	0.20	06/05/2017	(\$250)
05/30/17	0.20	06/05/2017	(\$80)
06/01/17	1.19	06/05/2017	\$ 570
05/01/17	2.99	06/05/2017	\$ 556
	06/09/17 06/06/17 06/01/17 05/30/17 06/01/17	06/09/17 0.34 06/06/17 0.30 06/01/17 1.50 (100% profit Rule + Gap) 3.75 Sold Balance 05/30/17 0.20 05/30/17 0.20 06/01/17 1.19	06/09/17 0.34 06/07/2017 06/06/17 0.30 06/09/2017 06/01/17 1.50 06/07/2017 (100% profit Rule + Gap) 06/09/2017 3.75 Sold Balance 05/30/17 0.20 06/05/2017 05/30/17 1.19 06/05/2017

Recommendations will be both listed in this letter and texted to members.

Previous closed out stock and option positions can be found in past Market Strategies Newsletter issues available in the VIP Subscribers Members Area.

This Weeks' Economic Numbers Earnings Releases and Media Data

Before the Open on top of the Row; After the close below the Economics Information

MONDAY	Hamilton Lane HLNE 0.24
	Pinnacle Financial Partners holds a merger meeting Markets in Australia and Russia are closed
	Cavco Industries CVCO (1.02 vs 0.77) Dominion Diamond DDC (0.05 vs -0.01) Science Applications SAIC (1.04 vs 0.80)
TUESDAY	Dorian LPG LPG (-0.14 vs 0.60) FANG SFUN (-0.01 vs -0.23) John Wiley & Sons JWA (0.54 vs 0.67) Motorcar Parts of America MPAA (0.60 vs 0.50) A Senate Committee examines the President's proposed budget. Another committee looks at prescription drug prices 08:30 hrs PPI May (0.0% vs 0.5%) 08:30 hrs CORE PPI May (0.2% vs 0.4%) Capstone CPST (-0.12 vs -0.25) H&R Block HRB (3.53 vs 3.16) JIVE Software JIVE 0.02
WEDNESDAY	CSW Industrials CSWI 0.40 Leju Holdings LEJU (-0.21 vs -0.04) LibertyTX TAX 2.42vs2.32
	China Reports on Monthly Industrial Production and Retail Sales: 07:00 hrs MBA Mortgage Applications Index 06/10 (NA vs +7.1%) 08:30 hrs Retail Sales May (0.1% vs 0.4%) 08:30 hrs Retail Sales Ex-Auto (0.2% vs 0.3%) 08:30 hrs CPI May (0.0% vs 0.2%) 08:30 hrs CORE CPI May (0.2% vs 0.1%) 10:00 hrs Business Inventories April (-0.1% vs 0.2%) 10:30 hrs Crude Inventories 06/10 (NA vs +3.295Mln Bbls) 14:00 hrs FOMC Rate Decision June (1.125% vs 0.875%) The Fed is expected to raise rates by up to a quarter of a point.
THURSDAY	Jabil JBL (0.29 vs 0.17)Digital Turbine APPS -0.08 vs -0.09 Lakeland Ind LAKE 0.16vs0.00 Bob Evans BOBE (0.52 vs 0.48) Kroger KR (0.57 vs 0.70) Jamba JMBA -0.07 vs -0.28 Hain
THURSDAT	Celestial HAIN (0.56 vs 0.55) ReneSola SOL (-1/08 vs 0.06) Yingli Green Energy YGE (-2.55 vs 0.60) Nordic American Offshore NAO (-0.13 vs -0.30) 08:30 hrs Initial Claims 06/10 (240K vs 245K) 08:30 hrs Continuing Claims 06/03 (NA vs 1917K) 08:30 hrs Empire Manufacturing June (6.0% vs -1.0) 09:15 hrs Capacity Utilization May (78.7% vs 76.7%) 09:15 hrs Industrial Production May (0.0% vs 1.0%) 10:30 hrs Natural Gas Inventories 06/10 (NA vs 106 bcf) 16:00 hrs Net Long Term TIC Flows June (NA vs \$59.8Bln)
	Finisar FNSR (0.50 vs 0.29) Roadrunner Transportation RRTS (0.15 vs 0.32) Cherokee VHKE (0.12 vs 0.34) Axovant Sciences AXON (-0.50)
FRIDAY	CardConnect CCN (0.02)
	08:30 hrs Housing Starts May (1227K vs 1172K) 08:30 hrs Building Permits May (1250K vs 1229K) 10:00 hrs Michigan Sentiment - Prelim June (97.0 vs 97.1) Centene and Corning meet with investors
	The U.S. Oil Rig Count increased by 13 Rigs to 741 There are 408 more rigs targeting oil than last

year. 733 Rigs are drilling for oil. The Nat Gas Rig count decreased by 3 to a total of 183 making a total rig count of 916. It was the twenty first weekly rig count rise mostly in a row. Crude closed lower at \$45.83, down 3.8% or \$1.83. Natural Gas closed the week up \$0.04 or + 1.3%, at \$3.039

Undervalued Small Cap Stocks

Lower priced stocks that look to be a buy:

Lower Capitalized Companies with Great Potential

RMS Medical Products (REPR: \$ 0.45) "RMS" or the "Company" is pleased to announce that the umbrella organization of the public health insurance in Germany approved the FREEDOM60[®] Infusion System for reimbursement. The FREEDOM60[®] System was registered January, 31st 2017 and listed in the Medical Device Registry in the category mechanical infusion pumps. It is the ONLY device of its kind registered within Germany.

In partnership with **ContraCare** GmbH, a leader in Germany for Contract Management (reimbursement services) and managed Care, the RMS FREEDOM60[®], FreedomEdge[®], RMS Precision Flow Rate Tubing[™] and RMS HIgH-Flo Subcutaneous Safety Needle Sets[™] are now poised to dominate this growing market in Europe.

The United States Food and Drug Administration ("FDA") renewed the Company's Certificate to Foreign Government ("CFG"). A CFG is issued for legally marketed devices in the U.S. that are in compliance with the requirements of the Federal Food, Drug, and Cosmetic Act ("FFDCA"). A CFG is required by many market regulators in Asia, Europe, the Middle East and Latin America in order to legally sell medical devices in their territories. The renewal of this CFG confirms RMS devices have been cleared for sale in the U.S. and are in compliance with the requirements of the FFDCA. The CFG can be presented to regulators in foreign markets as part of the medical device registration process. Foreign governments often seek official assurance that products exported to their countries can be marketed in the U.S. and meet specific U.S. regulations, for example, current Good Manufacturing Practice ("cGMP") regulations and Quality System Regulations ("QSR").

Torsten Kühn, Chief Executive Officer of ContraCare, commented "as a premium service provider in Germany's health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HIgH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany's public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement."

Eric Bauer, Chief Operating Officer of RMS commented, "It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life."

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest Freedom Edge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

Enzo Biochem (ENZ: \$10.38)

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year it was up 54.22% versus the Dow Jones +13%. The relative strength index was 53.41 which is neutral and short interest declined to 827,800 shares. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court.

What do I look for in 2017? The market will be interesting in the first half with the Government transition to a new administration. Abbots Summary Judgement request was denied by the Court but the trial date has yet to be set. At some point the 2nd Court of Appeals will rule on Enzo's appeal on the CT. Courts reversal of the Jury's decision in the Enzo vs. Apalera Case. The market is giving no value, win or lose, to this decision. The stake is \$65 million with no adverse effect if ruled against Enzo. Enzo should again outperform the Dow and S&P in 2017.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.

When the company gets a 500 million dollar market cap (\$10.63) they will qualify for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIO (5.95)*

Reversed 1 for 30 on June 5th

Recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

The hiring of Mr Damasio will allow the Company's CEO Mr Richard T Schumacher, who has been the company's interim CFO for the past two years, and who has been a successful serial life sciences entrepreneur with three successful publicly traded companies to his credit, time to focus on critical operational issues in 2017.

Some issues to be attended to include a pending up-list to NASADAQ and their stated goal to build a field sales team this year.

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is "bottlenecked" by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and/or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking – the requirements of which drive a large and growing worldwide market.

PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure.

This process, called <u>pressure cycling technology</u>, <u>or PCT</u>, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch ("*psi*") or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and

specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid ("DNA"), ribonucleic acid ("RNA"), proteins, lipids and small molecules.

Their laboratory instrument, the Barocycler[®], and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction ("PULSE") tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their PCT Sample Preparation System ("PCT SPS").

The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;
- Pathogen inactivation (useful in vaccine development, infectious disease research, and more);
- Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);
- and immunodiagnostics (useful in the development and detection of biomarkers).

INTELLECTUAL PROPERTY

PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.

NightFood, Inc. (NGTF 0. 30)*

Has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.

People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or "bites".

Consumers spend over \$50 billion/year on night-time snacks...over \$1B every week. In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies.

Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We've seen it happen with low-carb, we've seen it happen with gluten-free. Can it happen with nighttime snacking as well?

Leo Motors (LEOM: \$ 0. 11)* has patents for the electric battery industry which we will be writing about in upcoming weekly reports. They have developed a lithium battery that can operate vehicles in sub-zero climates. Their subsidiary LGM has developed battery technology supported by the Korean government to make it possible to use electric battery technology for fishing boats. They have a cartridge system which is a light-weight replacement method of swapping electric batteries.

Fishing has been harmed by the noise and oil leaks from internal combustion engines. LGM has solved that problem and besides eliminating the toxic problem, operating costs are reduced by 25%.

In addition they have a special patent for averting electric hazards and shocks. Leo developed the Internet of Things for e-boats which is networked and connected with an Android Operating System. Leo's power supply system is CAN (Controller Area Network) based, which enables mobile diagnostics between mobile devices and boats using the Leo technology.

Leo is developing a battery swap system for Kalmado in Puerto Princesa, Philippines, a world famous tourist attraction, which is focused on green energy. They will be converting 100 boats as the environment is expected to become 100% free of the toxicity from internal combustion engines. Also, Leo has developed a battery swap system for Go-Karts to be used in malls in China, Korea and Myanmar. Leo Motors has a new carbon nanotube battery power pack that functions and supplies full power in extreme low temperatures such as below 49 degrees without the need for grid electricity.

Skinvisible (SKVI: \$ 0.027)*:

SKVI has developed skin care products using its patented Invisicare polymer delivery systems and transdermal cannabis products from hemp-derived CBD, with its new developments to include cannabinoids from marijuana CBD and THC.

Rule 17B Attestations and Disclaimers

Princeton Research, Inc. has approximately 2,581,578 shares of AIVN both free and restricted and represents them for Investor relations. Princeton also has about 40,000 shares of TXGE. Princeton is paid \$ 1,500 per month from RMS Medical Products. Princeton has bought 81,100 shares of RMS Medical Products. Princeton was paid \$ 2,500 to write a report on Xinergy. Princeton has signed a contract with CBLI to be paid \$ 2500 for July and August for investor relations. Princeton has been engaged by Target Energy. No contract is currently in place. Princeton was paid about 500,000 restricted shares of Leo Motors.

When there is no movement in penny stocks, even though there is none or very small losses, we will liquidate (sold AIVN on stop) even though we like the company, if money is needed for better opportunities.

We now believe REPR represents upside opportunity. The Target ADR trades at about \$ 4.50 in U.S. vs 0.05 in Australia. Princeton owns 400,000 Australia shares and about 900 U.S. ADR's.

Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this e-mail issue. Princeton may buy or sell its free-trading shares in companies it represents at any time.

CONTACT

Please Direct All Inquiries To:

Mike King (702) 650-3000 mike@princetonresearch.com

Charles Moskowitz (781) 826-8882 CAM@MoneyInfo-LLC.com

Princeton Research 3887 Pacific Street, Las Vegas, Nevada 89121

Fax: (702) 697-8944

www.PrincetonResearch.com